Your browser doesn't support javascript.
loading
Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
Süren, Elçin; Özkaya, Dilek; Çetinkaya, Ersan; Kalayci, Mustafa; Yigit, Kenan; Kücük, Mehmet Fatih; Erol, Muhammet Kazim.
Afiliación
  • Süren E; Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.
  • Özkaya D; Department of Ophthalmology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
  • Çetinkaya E; Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey. ersan_cetinkaya@hotmail.com.
  • Kalayci M; Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.
  • Yigit K; Department of Ophthalmology, Kayseri City Hospital, Kayseri, Turkey.
  • Kücük MF; Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.
  • Erol MK; Department of Ophthalmology, Antalya Training and Research Hospital, Antalya, Turkey.
Int Ophthalmol ; 42(6): 1905-1913, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35094229
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinopatía de la Prematuridad / Ranibizumab Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Infant / Newborn Idioma: En Revista: Int Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinopatía de la Prematuridad / Ranibizumab Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans / Infant / Newborn Idioma: En Revista: Int Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Países Bajos